Details of Disease

General Information of Disease (ID: DISWH7BV)

• Disease Name: Thyrotoxicosis
• Synonyms: GRD; hyperthyroidism, autoimmune; Graves disease, susceptibility to, 1; GRD1
• Disease Class: 5A02: Thyrotoxicosis
• Definition: A hypermetabolic syndrome caused by the elevation of thyroid hormone levels in the serum. Signs and symptoms include tachycardia, palpitations, tremor, weight loss, warm weather intolerance, and moist skin. Causes include Graves disease, toxic nodular goiter, toxic thyroid nodule, and lymphocytic thyroiditis.
• Disease Hierarchy:
  DISU4KOQ: Graves disease
  DISWH7BV: Thyrotoxicosis
• ICD Code:
  ICD-11: ICD-11: 5A02
  Expand ICD-11: '5A02
  Expand ICD-10: 'E05; 'E05.8; 'E05.9
• Disease Identifiers:
  MONDO ID: MONDO_0010138
  MESH ID: D013971
  UMLS CUI: C0040156
  MedGen ID: 11814
  SNOMED CT ID: 286909009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Potassium iodide	DMPO7S1	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADRA2A	TTWG9A4	moderate	Biomarker	[2]
MTHFR	TTQWOU1	Strong	Genetic Variation	[3]
TSHR	TT6NYJA	Strong	Biomarker	[4]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A2	DTQ8MP1	moderate	Biomarker	[5]

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
RNH1	OT6EC79B	moderate	Biomarker	[6]
SHC3	OT305NPA	moderate	Biomarker	[6]
TG	OT3ELHIJ	moderate	Biomarker	[7]
TNS3	OTPG2D8Z	moderate	Biomarker	[8]
CYTB	OTAHB98A	Strong	Biomarker	[9]
IYD	OT8BQWTE	Strong	Altered Expression	[10]
SERPINA7	OTUYVTSU	Strong	Biomarker	[11]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Global Disruption of 2A Adrenoceptor Barely Affects Bone Tissue but Minimizes the Detrimental Effects of Thyrotoxicosis on Cortical Bone.Front Endocrinol (Lausanne). 2018 Aug 28;9:486. doi: 10.3389/fendo.2018.00486. eCollection 2018.
• [3] Cerebral sinus venous thrombosis in a subject with thyrotoxicosis and MTHFR gene polymorphism.Neurol Sci. 2008 Oct;29(5):343-5. doi: 10.1007/s10072-008-0992-4. Epub 2008 Oct 21.
• [4] Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419843690. doi: 10.1177/2058738419843690.
• [5] Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.Lancet Diabetes Endocrinol. 2019 Sep;7(9):695-706. doi: 10.1016/S2213-8587(19)30155-X. Epub 2019 Jul 31.
• [6] Thyroid cancer post radioactive iodine treatment for hyperthyroidism - case series and review of the literature.Endokrynol Pol. 2017;68(5):561-566. doi: 10.5603/EP.a2017.0037. Epub 2017 Jun 6.
• [7] Autoantibody heritability in thyroiditis: IgG subclass contributions.Autoimmunity. 2011 May;44(3):195-200. doi: 10.3109/08916934.2010.515275. Epub 2010 Oct 1.
• [8] Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis.Thyroid. 2004 Mar;14(3):187-90. doi: 10.1089/105072504773297858.
• [9] Effect of experimental thyrotoxicosis on oxidative phosphorylation in rat liver, kidney and brain mitochondria.Mol Cell Endocrinol. 1982 Oct;28(2):173-89. doi: 10.1016/0303-7207(82)90030-2.
• [10] Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
• [11] Normal cellular uptake of thyroxine from serum of patients with familial dysalbuminemic hyperthyroxinemia or elevated thyroxine-binding globulin.J Clin Endocrinol Metab. 1988 Dec;67(6):1166-70. doi: 10.1210/jcem-67-6-1166.